These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20133200)

  • 1. LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles.
    Doody K; Devroey P; Gordon K; Witjes H; Mannaerts B
    Reprod Biomed Online; 2010 Apr; 20(4):565-7. PubMed ID: 20133200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa.
    Doody KJ; Devroey P; Leader A; Witjes H; Mannaerts BM
    Reprod Biomed Online; 2011 Oct; 23(4):449-56. PubMed ID: 21856230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH.
    Griesinger G; Shapiro DB; Kolibianakis EM; Witjes H; Mannaerts BM
    Reprod Biomed Online; 2011 Oct; 23(4):457-65. PubMed ID: 21843970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
    Borm G; Mannaerts B
    Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial.
    Allegra A; Marino A; Coffaro F; Scaglione P; Sammartano F; Rizza G; Volpes A
    Hum Reprod; 2007 Jan; 22(1):101-8. PubMed ID: 17032732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.
    Wang HL; Lai HH; Chuang TH; Shih YW; Huang SC; Lee MJ; Chen SU
    PLoS One; 2016; 11(4):e0154123. PubMed ID: 27100388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.